SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment.
作者信息
Rebeaud Mathieu E, Zores Florian
机构信息
DBMV, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Groupe médical spécialisé, Strasbourg, France.
出版信息
Front Med (Lausanne). 2020 Apr 24;7:184. doi: 10.3389/fmed.2020.00184. eCollection 2020.
Abstract
摘要
相似文献
1
SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）与氯喹作为抗病毒治疗的应用
Front Med (Lausanne). 2020 Apr 24;7:184. doi: 10.3389/fmed.2020.00184. eCollection 2020.
2
Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV).2019新型冠状病毒（2019-nCoV）与严重急性呼吸综合征冠状病毒（SARS-CoV）之间的结构、糖基化及抗原变异
Virusdisease. 2020 Mar;31(1):13-21. doi: 10.1007/s13337-020-00571-5. Epub 2020 Mar 5.
3
Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.一种广谱抗冠状病毒药物对SARS-CoV-2主要蛋白酶的抑制作用的结构基础
Am J Cancer Res. 2020 Aug 1;10(8):2535-2545. eCollection 2020.
4
SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries.严重急性呼吸综合征冠状病毒2：鉴于严重急性呼吸综合征冠状病毒抗病毒药物的发现，对潜在抗病毒药物的最新情况介绍
Vaccines (Basel). 2020 Jun 23;8(2):335. doi: 10.3390/vaccines8020335.
5
Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses.2019新型冠状病毒（nCoV）刺突蛋白的结构建模显示，与严重急性呼吸综合征冠状病毒（SARS-CoV）及相关类SARS冠状病毒相比，其蛋白水解敏感激活环是一个显著特征。
bioRxiv. 2020 Feb 18:2020.02.10.942185. doi: 10.1101/2020.02.10.942185.
引用本文的文献
1
Multi-Component Synthesis of New Fluorinated-Pyrrolo[3,4-]pyridin-5-ones Containing the 4-Amino-7-chloroquinoline Moiety and In Vitro-In Silico Studies Against Human SARS-CoV-2.含4-氨基-7-氯喹啉部分的新型氟化吡咯并[3,4-]吡啶-5-酮的多组分合成及针对人类SARS-CoV-2的体外-计算机模拟研究
Int J Mol Sci. 2025 Aug 7;26(15):7651. doi: 10.3390/ijms26157651.
2
Plasma-activated water: Candidate hand disinfectant for SARS-CoV-2 transmission disruption.等离子体活化水：用于破坏SARS-CoV-2传播的候选手部消毒剂。
Heliyon. 2024 Jul 9;10(15):e34337. doi: 10.1016/j.heliyon.2024.e34337. eCollection 2024 Aug 15.
3
Mechanisms Underlying the Effects of Chloroquine on Red Blood Cells Metabolism.氯喹对红细胞代谢影响的作用机制。
Int J Mol Sci. 2024 Jun 11;25(12):6424. doi: 10.3390/ijms25126424.
4
Interferon-stimulated gene PVRL4 broadly suppresses viral entry by inhibiting viral-cellular membrane fusion.干扰素刺激基因PVRL4通过抑制病毒与细胞膜融合广泛抑制病毒进入。
Cell Biosci. 2024 Feb 17;14(1):23. doi: 10.1186/s13578-024-01202-y.
5
Mechanistic-Based Classification of Endocytosis-Related Inhibitors: Does It Aid in Assigning Drugs against SARS-CoV-2?基于机制的内吞作用相关抑制剂分类：它有助于对抗 SARS-CoV-2 的药物分类吗？
Viruses. 2023 Apr 23;15(5):1040. doi: 10.3390/v15051040.
6
Solar Photocatalysis for the Decontamination Of Water from Emerging Pharmaceutical Pollutant Chloroquine Using Nano ZnO as the Catalyst.以纳米氧化锌为催化剂的太阳能光催化去除水中新兴药物污染物氯喹
Water Air Soil Pollut. 2023;234(3):146. doi: 10.1007/s11270-023-06148-4. Epub 2023 Feb 17.
7
Emetine in Combination with Chloroquine Induces Oncolytic Potential of HIV-1-Based Lentiviral Particles.埃替啡与氯喹联合诱导基于 HIV-1 的慢病毒颗粒的溶瘤潜力。
Cells. 2022 Sep 10;11(18):2829. doi: 10.3390/cells11182829.
8
Deep learning-based molecular dynamics simulation for structure-based drug design against SARS-CoV-2.基于深度学习的分子动力学模拟用于针对严重急性呼吸综合征冠状病毒2的基于结构的药物设计。
Comput Struct Biotechnol J. 2022;20:5014-5027. doi: 10.1016/j.csbj.2022.09.002. Epub 2022 Sep 7.
9
3D Lung Tissue Models for Studies on SARS-CoV-2 Pathophysiology and Therapeutics.用于研究 SARS-CoV-2 发病机制和治疗方法的 3D 肺组织模型。
Int J Mol Sci. 2022 Sep 3;23(17):10071. doi: 10.3390/ijms231710071.
10
Comparison of Cell Fusions Induced by Influenza Virus and SARS-CoV-2.流感病毒和 SARS-CoV-2 诱导的细胞融合比较。
Int J Mol Sci. 2022 Jul 1;23(13):7365. doi: 10.3390/ijms23137365.
本文引用的文献
1
Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.氯喹和羟氯喹在治疗伴有或不伴有糖尿病的2019冠状病毒病中的应用：一项系统检索及叙述性综述，特别提及印度和其他发展中国家
Diabetes Metab Syndr. 2020 May-Jun;14(3):241-246. doi: 10.1016/j.dsx.2020.03.011. Epub 2020 Mar 26.
2
A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.仓促下结论？有关羟氯喹治疗 COVID-19 的快速报告和结果传播及其后果。
Ann Intern Med. 2020 Jun 16;172(12):819-821. doi: 10.7326/M20-1223. Epub 2020 Mar 30.
3
Potential Effects of Coronaviruses on the Cardiovascular System: A Review.冠状病毒对心血管系统的潜在影响：综述。
JAMA Cardiol. 2020 Jul 1;5(7):831-840. doi: 10.1001/jamacardio.2020.1286.
4
Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.在大流行期间治疗新冠病毒病——超说明书用药、同情用药及随机临床试验
JAMA. 2020 May 19;323(19):1897-1898. doi: 10.1001/jama.2020.4742.
5
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
6
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].《磷酸氯喹治疗新型冠状病毒肺炎专家共识》
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188. doi: 10.3760/cma.j.issn.1001-0939.2020.03.009.
7
Of chloroquine and COVID-19.关于氯喹和 COVID-19。
Antiviral Res. 2020 May;177:104762. doi: 10.1016/j.antiviral.2020.104762. Epub 2020 Mar 5.
8
COVID-19 and the cardiovascular system.新型冠状病毒肺炎与心血管系统。
Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
9
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
10
Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.中国 2019 年冠状病毒病（COVID-19）的胸部 CT 与 RT-PCR 检测的相关性：1014 例报告。
Radiology. 2020 Aug;296(2):E32-E40. doi: 10.1148/radiol.2020200642. Epub 2020 Feb 26.
Zotero 插件